Mathew Barker

[Mathew Barker @MathewBarker11]

@miradreaamy 35

[Mathew Barker @MathewBarker11]

@miradreaamy 128

[Mathew Barker @MathewBarker11]

@Batmantallk 100

[Mathew Barker @MathewBarker11]

@farman4x 12

[Mathew Barker @MathewBarker11]

It works !

[Sean Dent @SeanDentBsc]

In 2023, Novartis' global head of drug development said #AVCT's pre|CISION platform is doing exactly what it was designed to do: deliver a RANGE of chemotherapies across MULTIPLE different tumour types and it was demonstrating *very impressive* tolerability to-date.

All that remained was to demonstrate the common sense thesis that putting MORE of a drug KNOWN to be efficacious into a tumour would lead to enhanced efficacy. Not rocket science, "that bit has already been done ;-)".

Fast-forward 24 months to now:-
• 2-weekly dosing confirmed safe
• No MTD found despite dosing at 4x max dose strength & up to max cumulative dose of 550mg/kg
• Cardiotoxicity eliminated
• 100 - 1 tumour/plasma ratio

**• 91% DCR rate achieved in SGC
• PFS more than doubled in SGC & still improving
**
Sounds like enhanced efficacy to me, but Avacta weren't finished there...

They then bolted exetecan (the most potent topo1 inhibitor) onto pre|CISION and found
• 75x improvement in therapeutic index
• half-life extension from hrs to days
• Developed a range of linkers and capping groups to modulate drug delivery
• in-vivo multiple complete durable responses

* sounds like further efficacy signs to me, but Avacta weren't done there...

They then developed AVA6207, which delivers 2 warheads to the tumour simultaneously (just showing off now) & that also shows same the same thing which AVA6K, AVA3996 & AVA6103 have shown: that this really works.

The holy grail in cancer treatment is to target tumours and spare healthy tissue and Avacta are doing it across a range of tumour types, with a range of warheads in a range of settings.

Fast-forward to June 2026, circa 30 months since Janet's comments and it's highly likely Avacta can add the following list of achievements to it's CV

• AVA6103 proved to be safe in humans & early signs of efficacy (remember, exetecan has already overcome resistance to irinotecan and is more permeable than deruxtecan which is used in Enhertu)
* there's the word "efficacy again" 👀
• AVA6K proven safe & showing early signs of efficacy in breast cancer indication
• ODD status achieved for SGC (on- top of already having it for STS)
• Clear pathway for Accelerated approval/ FDA fast-track
• Strong efficacy signals from P1B (STS & SGC).

Now, let's remember some of the advantages pre|CISION has over ADC's:-
1. 10x cheaper to make
2. Micropeptide unseen by immune system
3. No acquired resistance or loss of target
4. None of the off-target toxicities such as pneumonitis
5. It targets FAP which is expressed in 90% of solid tumours
6. Is works by the bystander effect

So pre|CISION is far cheaper, drastically better & much more broadly applicable than ADC's which big pharma have spent £XXXBn developing. Notably, Novartis are the BP who have hitherto spent the least on ADC development which could be critical as negotiations and bids intensify.

There's a LOT more I've not said such as AVA7100 development, agreement with Tempus etc but the point I want to make here is that it's really not a question of IF Avacta get bought out, it's for how much. I think the "when" is now slowly coming into focus also.

Who blinks first because as CC said "Game Over. It works" 🍿😬

[RAH @RAH00084]

Arguably the clearest steer #AVCT has provided as to what happened before Christmas…

Talks became highly extended. No reflection on platform. We then ran out of cash. And here we are.

[Cumulus @Cumulus51896691]

@neutronicLSE The patient in this image was a late stage pre treated STS sufferer, who was able to be on chemo for over a year without significant side effects and saw his widespread tumors shrink nearly away. Just saying. #avct

[Mathew Barker @MathewBarker11]

@PortageBiotech @mattpillar Are you joking ?
I’ve just lost half of my pension in Portage with this CFO !!

[Christina Coughlin @coughlin582]

A great discussion with @ICRConsilium about our pipeline and #AACR24 data update. Grateful for the opportunity.

[Nacapital @NAJJCAPITAL]

#avct unbelievable

[Marty McFly @Blueberrymgmnt]

#AVCT

@coughlin582 is very good. @avacta is maturing overnight with her delivering quality, directed messaging on the *platform*. It’s night and day.

🎯 Additional approaches: Platform.
🎯 Antibody: Biologic agnostic.
🎯 Approaches in clinic: Partnerships.

@ICRConsilium

[Cumulus @Cumulus51896691]

@Blueberrymgmnt @coughlin582 @avacta @ICRConsilium She hits a lot of key points in a very short space. Encouraging signals of efficacy of communication from Avacta emerging now.

[⛏🅾️Ⓜ️💣 @tom_the_bomb__]

The patients in this phase were not expected to receive any clinical benefit.

Multiple patients remain on trial.

#AVCT is rewriting the rules in #oncology.

#AACR24

[Christina Coughlin @coughlin582]

AVA6000: FAP-enabled release of doxorubicin directly in the TME results in a favorable safety profile, tumor responses and a wider therapeutic index @Avacta

#LetsDoThis
#PeptidesCreateHope

#AACR24👇

[Christina Coughlin @coughlin582]

We are very excited to be heading to San Diego for the data release for @Avacta. Full updated data from the Phase 1 trial of AVA6000. Looking to Tuesday's session at #AACR2024

Check our next chapter at https://t.co/cMNWHpN28b

See you Tuesday!

#PeptidesCreateHope
#LetsDoThis

[Avacta @avacta]

In the new R&D Spotlight Series we will take you a little deeper into the science behind the Avacta Therapeutics pipeline. In the first episode today we're going to introduce you to two of our key chemists who are working on the preCISION platform. https://t.co/jK9lGjBNJF #AVCT

[Myles McNulty @MylesMcNulty]

Currently in the middle of moving homes (and cities!), last/this week, so haven't had much time to post on here. Will try to get a few in over the next several days when I can, on the various open trades and investments.

First up, Avacta #AVCT:

Over the past week we've seen considerable churn from the placing, coupled with a number of private investors evidently throwing in the towel - despite the share price being at a 24-month low, and despite the company now being fully funded for 2+ years. However, such actions are understandable (to a degree), given how frequently and how massively Avacta's mgmt and board have managed to mess things up over the last 4 years.

That said, I thought the #AVA6000 update last Thursday was fantastic. A maximum tolerated dose was still not found in cohort 7 of the three-weekly dosing arm, which is just extraordinary. Recall that @avacta's management had anticipated an MTD to be found by cohort 3 or 4, prior to the trial commencing. That puts into light just how extraordinarily targeted the pre | CISION platform is.

In fact, so incredible have been the results of the first seven cohorts, that Avacta has launched a second arm of escalating cohorts - namely, two-weekly dosing. This should really crank up the efficacy of AVA6000 (given that a patient will be dosed with 50% more drug over a given time period in the two-weekly arm, than they would be in the three-weekly arm).

The three patients in cohort 1 of this two-weekly arm have now been dosed. Given that the company now has considerable PK data from the first arm, the trial investigators will have a good idea of how many cohorts will be required in this second arm (which I believe will be 2-4). As a result, they think they'll be able to launch efficacy studies - which will lead straight into a Pivotal Phase 2 study - in H2.

Feasibly, Avacta could be generating revenue from sales of AVA6000 by early 2026. Said revenue could rapidly become (many) multiples of Avacta's current mkt cap, per annum.

8 more trading sessions, and Avacta will be presenting new data for the AVA6000 trial at a (or rather, the) major cancer treatment conference, AACR. I am hopeful that the company has been holding back some very punchy efficacy data for it (major tumour shrinkage across an array of patients), to really make a bang.

Whilst the data itself may not necessarily act as a share price catalyst, I'm looking for this first commercial deal to land (Pfizer, Novartis?) around AACR, or not too long after. There is form for announcing major deals in the biotech industry around such conferences, to really publicize it and cause a stir.

This time around, Avacta will be presenting its pre | CISION platform as a direct competitor to the antibody-drug conjugate class, which is the hottest cub-class in oncology. About time!

Avacta's current share price (50.75p!) hardly makes one feel as though the company is sitting on anything particularly special. But the data does not lie. And we'll have a whole load more, very shortly.

And, as we've seen countless times with this stock, sentiment can swing the other way in an instant. I fully expect it to for Avacta, very soon. The company is fully cashed up to get AVA6000 (which seems destined to be a blockbuster drug) right into a Pivotal Phase 2; and it's looking to make a mega splash - with maximum publicity - in the next couple of weeks.

Buying the shares at around a 24-month low today, just a couple of weeks before what could be a major unveiling of exceptional clinical data (and hopefully, a bloody licensing deal!!), is a good for me.

Time for management to be "boosters" of their share price!

[RAH @RAH00084]

*and* the PK profile for these patients suggests all can receive more doxorubicin.

Consider these patients were dosed in the Q2W at 200mg and 250mg levels.

#AVCT began the 5th cohort (250mg) on 5 April 2023 and 4th (200mg) on 1 Sept 2022.

When Cohort 4 completed AVCT said this:

“AVA6000 continues to be well tolerated by patients in cohort 4 with a marked reduction in the incidence and severity of the typical toxicities associated with the standard doxorubicin chemotherapy administration. Typical toxicities include alopecia, myelosuppression, nausea, vomiting, mucositis and cardiotoxicity. Importantly, even at the highest dosing levels in cohort 4, equivalent to more than double the normal dose of doxorubicin, the typical drug-related cardiotoxicity of doxorubicin was not observed.”

So these SFT patients (let’s say they joined at the beginning of each cohort for ease of dates, even though they may not have joined for a few weeks) have been on-drug:

200mg (C4) - nearly 19 months since this cohort began;

250mg (C5) - nearly 12 months since this cohort began.

Even if you assume the SFT patient joined at the end of C4 (they won’t have, obviously) that’s over 12 months on drug.

12 months at 200mg.

75mg straight dox every 3 weeks, tops out at 18 weeks….

This patient is looking at a minimum of 48 weeks and likely far, far longer.

Yes. There may be dosing holidays but the PK even at this stage is suggestive that these patients can receive *more* AVA6000.

Market is asleep to what’s happening here.

50p? Ha!